S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

$17.30
+0.09 (+0.52%)
(As of 03/28/2024 ET)
Today's Range
$17.15
$17.53
50-Day Range
$13.69
$17.60
52-Week Range
$13.62
$21.95
Volume
365,527 shs
Average Volume
447,532 shs
Market Capitalization
$6.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.68

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
13.8% Upside
$19.68 Price Target
Short Interest
Healthy
3.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
35.38%
From $0.65 to $0.88 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.50 out of 5 stars

Medical Sector

337th out of 938 stocks

Ophthalmic Goods Industry

3rd out of 7 stocks

BLCO stock logo

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

BLCO Stock News Headlines

BLCO Apr 2024 17.500 call
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
BHC Feb 2024 10.000 put
Bausch + Lomb price target raised by $2 at Wells Fargo, here's why
Q4 2023 Bausch + Lomb Corp Earnings Call
Needham Reaffirms Their Hold Rating on Bausch + Lomb Corporation (BLCO)
Bausch + Lomb gains after earnings beat
Emergent BioSolutions Appoints Joseph Papa As President And CEO
Bausch + Lomb Q4 Adj. Net Income Rises
Bausch + Lomb Q4 2023 Earnings Preview
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
N/A
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.68
High Stock Price Target
$25.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+13.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-4.00%

Debt

Sales & Book Value

Annual Sales
$4.15 billion
Cash Flow
$1.95 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.07 billion
Optionable
Optionable
Beta
0.35
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Osama A. Eldessouky (Age 52)
    Executive VP & CFO
    Comp: $1.09M
  • Dr. Yehia Hashad M.D. (Age 57)
    Executive VP of Research & Development and Chief Medical officer
    Comp: $1.09M
  • Mr. Brenton L. Saunders J.D. (Age 54)
    CEO & Chairman
  • Mr. Alan Waterhouse CPFA (Age 64)
    MBA, Executive VP and Chief Supply Chain & Operations Officer
  • Mr. Frederick J. Munsch (Age 53)
    Senior VP, Controller & Chief Accounting Officer
  • Mr. A. Robert D. Bailey (Age 61)
    Executive VP & Chief Legal Officer
  • Mr. Jonathon L. Kellerman
    Chief Compliance Officer
  • T.J. Crawford
    Chief Communications Officer
  • Dr. Manisha A. Narasimhan Ph.D. (Age 47)
    Chief Corporate Development & Digital Officer
  • Ms. Asli Gevgilili
    Executive VP & Chief Human Resources Officer

BLCO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BLCO shares.
View BLCO analyst ratings
or view top-rated stocks.

What is Bausch + Lomb's stock price target for 2024?

10 Wall Street analysts have issued 12 month target prices for Bausch + Lomb's shares. Their BLCO share price targets range from $16.00 to $25.00. On average, they expect the company's stock price to reach $19.68 in the next year. This suggests a possible upside of 13.8% from the stock's current price.
View analysts price targets for BLCO
or view top-rated stocks among Wall Street analysts.

How have BLCO shares performed in 2024?

Bausch + Lomb's stock was trading at $17.06 at the start of the year. Since then, BLCO shares have increased by 1.4% and is now trading at $17.30.
View the best growth stocks for 2024 here
.

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 1,230,000 shares, a decline of 20.1% from the February 29th total of 1,540,000 shares. Based on an average trading volume of 449,000 shares, the short-interest ratio is presently 2.7 days. Currently, 3.2% of the shares of the stock are short sold.
View Bausch + Lomb's Short Interest
.

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our BLCO earnings forecast
.

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) released its earnings results on Wednesday, February, 21st. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.07. The company earned $1.17 billion during the quarter, compared to the consensus estimate of $1.11 billion. Bausch + Lomb had a positive trailing twelve-month return on equity of 3.70% and a negative net margin of 6.27%. The business's revenue for the quarter was up 17.8% on a year-over-year basis. During the same quarter last year, the business posted $0.23 EPS.

What ETFs hold Bausch + Lomb's stock?

ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX).

What guidance has Bausch + Lomb issued on next quarter's earnings?

Bausch + Lomb issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $6.1 billion.

When did Bausch + Lomb IPO?

Bausch + Lomb (BLCO) raised $788 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Bausch + Lomb's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FIL Ltd (2.31%), River Road Asset Management LLC (0.55%), Freshford Capital Management LLC (0.50%), Whitebox Advisors LLC (0.27%), Victory Capital Management Inc. (0.16%) and Gabelli Funds LLC (0.09%).

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners